NASDAQ: VKTX Viking Therapeutics, Inc. 10-Q

Viking advances VK2735 to Phase 3, but Ligand disputes VK2809 license; cash burn triples

Filed April 30, 2026 · Period ending March 31, 2026 · Compared to 10-Q Apr 24, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade VKTX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.